RUNX1 and acute myeloid leukemia: No toxicity-related deaths or unexpected adverse events were reported.<h4>Conclusion</h4>The incorporation of olaparib into the conditioning regimen demonstrated favorable safety and efficacy, inducing rapid CMR and durable remission in high-risk relapsed/refractory RUNX1::RUNX1T1+ AML patients.